4 July 2018 - Deborah Wilkes
Bristol-Myers Squibb is considering a range of strategic options, including divestment, for its French consumer healthcare business UPSA.
The company said the strategic review would evaluate the "financial potential of UPSA, its future commercial potential and opportunities for growth". A range of options – including a potential sale of UPSA and retaining the business – are under consideration.
Bristol-Myers Squibb said the review should be completed by the end of 2018.
Founded in 1935, UPSA has its headquarters in France and operates in 60 countries, mainly in Europe. It generates annual sales of EUR425 million (USD495 million) from a portfolio of brands including: the Aspirine UPSA, Dafalgan and Efferalgan pain relievers; Donormyl sleep aid; and Fervex cold and flu remedies.
Bristol-Myers Squibb said UPSA's manufacturing plant in Agen was a state-of-the-art facility employing more than 1,300 people.
Over the past decade, Bristol-Myers Squibb has divested a number of OTC businesses to Paladin Labs, RB and Taisho Pharmaceutical (click here to read more on the OTCToolbox Deals Database).